Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial

Phase 3 Completed 497 enrolled NCIC Clinical Trials Group National Cancer Institute (NCI) · collab North Central Cancer Treatment Group · collab SWOG Cancer Research Network · collab

NaSingle-groupQuadruple-blindDiagnostic

Summary

RATIONALE: Learning about the effect of exemestane and anastrozole on bone mineral density in postmenopausal women with primary breast cancer may help plan treatment, decrease the risk of broken bones, and help patients live more comfortably. PURPOSE: This phase III trial is studying bone mineral density in postmenopausal women with primary breast cancer who are receiving treatment on clinical trial CAN-NCIC-MA27.

Timeline

Start: 2006-04-24
Primary completion: 2011-03
Completion: 2012-01-06

Publications

Results Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM, Scher J, Pritchard KI, Elliott CR, Badovinac-Crnjevic T, St Louis J, Chapman JA, Shepherd LE. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. Lancet Oncol. 2014 Apr;15(4):474-82. doi: 10.1016/S1470-2045(14)70035-X. Epub 2014 Mar 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Alendronic Acid	Small molecule	—	Oral
Background	Risedronate	Small molecule	—	Oral
Background	calcium gluconate	Small molecule	—	—

Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial

Summary

Timeline

Publications

Drugs

Indications